



(51) International Patent Classification:

C07D 211/22 (2006.01) A61P 35/00 (2006.01)
A61K 31/445 (2006.01) A61P 35/02 (2006.01)

(21) International Application Number:

PCT/GB2011/051484

(22) International Filing Date:

5 August 2011 (05.08.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/371,648 6 August 2010 (06.08.2010) US
61/384,170 17 September 2010 (17.09.2010) US

(71) Applicant (for all designated States except MG, QA, US):
ASTRAZENECA AB [SE/SE]; SE-151 85 Södertälje (SE).

(71) Applicant (for MG, US only): ASTRAZENECA UK
LIMITED [GB/GB]; 2 Kingdom Street, London Greater,
London W2 6BD (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): DIEBOLD, Robert
Bruce [US/US]; AstraZeneca R&D Boston, 35 Gatehouse
Drive, Waltham, Massachusetts 02451 (US). GERO,
Thomas [US/US]; AstraZeneca R&D Boston, 35 Gate-


house Drive, Waltham, Massachusetts 02451 (US).
GROVER, Paul [US/US]; AstraZeneca R&D Boston, 35
Gatehouse Drive, Waltham, Massachusetts 02451 (US).
HUANG, Shan [CN/US]; AstraZeneca R&D Boston, 35
Gatehouse Drive, Waltham, Massachusetts 02451 (US).
IOANNIDIS, Stephanos [GR/US]; AstraZeneca R&D
Boston, 35 Gatehouse Drive, Waltham, Massachusetts
02451 (US). OGOE, Claude Afona [GH/US]; As-
traZeneca R&D Boston, 35 Gatehouse Drive, Waltham,
Massachusetts 02451 (US). SAEH, Jamal Carlos
[US/US]; AstraZeneca R&D Boston, 35 Gatehouse Drive,
Waltham, Massachusetts 02451 (US). VARNES, Jeffrey
Gilbert [US/US]; AstraZeneca R&D Boston, 35 Gate-
house Drive, Waltham, Massachusetts 02451 (US).

(74) Agent: ASTRAZENECA INTELLECTUAL PROP-
ERTY; SE-151 85 Södertälje (SE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,

[Continued on next page]

(54) Title: N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS



(57) Abstract: The present invention relates to compounds of Formula (I): and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds inhibit Bcl-2 and/or Bcl-X_L activities and may be used for the treatment of cancer.



TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*